Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
MUNICH, Germany, Sept. 2 /PRNewswire-FirstCall/ — Data presented today at the Annual Congress of the European Society of Cardiology showed that the investigational oral Factor Xa inhibitor DU-176b reduced the incidence of venous thromboembolism (VTE) compared with dalteparin among patients undergoing elective unilateral hip replacement surgery. There was a statistically significant dose response in efficacy (P
This randomized, double-blind comparative study examined the safety and efficacy of four doses of DU-176b (15, 30, 60 and 90 mg once daily) versus the low molecular weight heparin, dalteparin. The study was conducted among 903 patients in Europe and North America undergoing total hip replacement surgery.
“These findings are encouraging and we look forward to further study on this Factor Xa inhibitor,” said Gary Raskob, Ph.D., Dean, College of Public Health at the University of Oklahoma Health Sciences Center. “These findings indicate DU-176b may provide a high degree of efficacy, but further study is needed.”
“As the company that discovered one of the first Factor Xa small molecules (DX-9065a), we are proud to be building on our innovation in cardiovascular disease and tackling the need for better and more effective ways to prevent thrombosis,” said John Alexander M.D., president, Daiichi Sankyo Pharma Development. “We expect to commence phase III studies for DU-176b, targeting patients with atrial fibrillation, before the end of 2008.
Study Result Details VTE incidence (%) Bleeding occurrence*** (%) Dalteparin 43.8 [35.5-52.3]# 0 [0-2.1] DU-176b 15mg 28.2 [21.6-35.6]* 1.6 [0.3-4.5] 30mg 21.2 [15.0-28.6]** 1.8 [0.4-5.1] 60mg 15.2 [10.0-21.8]** 2.2 [0.6-5.4] 90mg 10.6 [6.2-16.6]** 2.3 [0.6-5.7] #95% confidence interval, * p=0.005, **p DU-176b is an oral anticoagulant that directly inhibits Factor Xa, a clotting factor in the blood. Daiichi Sankyo is developing DU-176b as a potential new treatment for the prevention of both arterial and venous thromboembolism. About Daiichi Sankyo A global pharmaceutical innovator, Daiichi Sankyo Co., Ltd., headed by President Takashi Shoda was established in 2005 through the merger of two leading Japanese pharmaceutical companies, Daiichi Pharmaceutical Co., Ltd. and Sankyo Co., Ltd. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development is cardiometabolic diseases, including therapies for thrombosis, dyslipidemia, hypertension, diabetes, and acute coronary syndromes. Equally important to the company is the discovery of new medicines in the areas of infectious diseases, cancer, bone and joint diseases, and immune disorders. For more information, visit http://www.daiichisankyo.com/. Daiichi Sankyo CONTACT: Toshiaki Sai, General Manager, Corporate CommunicationsDepartment of Daiichi Sankyo Company, Limited, +81-3-6225-1126; or KimberlyWix of Daiichi Sankyo, Inc. (United States), +1-973-695-8338, mobile +1-908-656-5447; or Dr. Felix Munzel of Daiichi Sankyo Europe, +49-(0)-89-7808-471 Web site: http://www.daiichisankyo.com/